ROR1 and B-cell chronic lymphocytic leukemia: Preclinical evaluation of the HSP90 inhibitor SNX-5422 in Ibrutinib-resistant CLL has furthermore been described, and destabilization of ROR1 enhances the activity of Ibrutinib against CLL in vivo [64,157].